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ABSTRACT 
 
The Effect of Moderate Consumption Of Non-Nutritive Sweeteners On Glucose 
Tolerance And Body Composition In Rats 
 
by 
 
Ashley Tovar 
 
John C. Young, Ph.D., Examination Committee Chair 
Professor, Kinesiology and Nutrition Sciences 
University of Nevada, Las Vegas 
 
 
Introduction: A comorbidity often seen with obesity is the development of impaired 
glucose tolerance. Abnormalities in the ability to metabolize glucose can lead to 
increased risk of developing pre-diabetes and if continued, diabetes mellitus type 2. To 
combat the effects of excess energy intake on obesity and glucose intolerance, low-
energy and non-nutritive sweeteners have been introduced as a replacement for 
traditional sucrose and fructose sweeteners that contribute more energy density. 
Limited research has been done concerning the effects of moderate consumption of 
nonnutritive sweeteners on blood glucose tolerance and body composition.  
Purpose: The purpose of this study was to determine the effect of moderate 
consumption of NNS (aspartame and sucrose) on glucose tolerance and body 
composition in an animal model. 
Methods: Sprague-Dawley rats (N=30) were housed in pairs in a 12 hr light/dark cycle. 
Animals were randomized into one of three groups where they were each fed a 
standard chow diet, with the inclusion of a treatment. Treatments include the addition of 
aspartame (8.5 mg/kg/day) or sucralose (2.6 mg/kg/day) to water, or a control of 
unflavored water. All animals were given food ad libitum for 6 weeks prior to testing and 
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sacrifice. The three treatment groups were as follows (n=10) aspartame (ASP), (n=10) 
sucralose (SUC), and (n=10) a control of water (CON). Assessments of lean mass and 
fat mass were determined from weighing of epididymal fat pads and the use of dual 
energy x-ray absorptiometry with small animal software prior to sacrifice at the 
completion of the 6 week treatment. After overnight fasting, an oral glucose tolerance 
test was administered. Blood glucose concentrations were measured with a tail prick 
sample, using a Bayer blood glucose monitor. Rats were then given an oral glucose 
load via oral gavage of 2 mg/kg, with samples then being taken every 15, 30, 60, and 
120 minutes of load with blood glucose being examined immediately. Insulin was 
collected from a tail bleed, with samples being stored at -70° C for later analysis. Insulin 
assessment was completed with the use of a radioimmunoassay for insulin sensitive 
rats. 
Results: Following the 6 week intervention treatment of water with aspartame (ASP), 
water with sucralose (SUC), or control (CON), no significant differences were seen in 
the results of oral glucose tolerance testing. ASP (10,150 ± 595 mg/dL/120 min, 
p=0.282) and SUC (9,147 ± 231 mg/dL/120 min, p=0.870) areas under the glucose 
concentration curve (AUC) were not significantly different from the CON group AUC 
(9147.85 ± 465 mg/dL/120 min). The areas under the insulin concentration curve were 
not significantly different between the NNS groups and the control (ASP p= 0.120, SUC 
p=0.456). Changes in body mass from the beginning of treatment to final were not 
significantly different between each of the NNS groups and the control group (ASP p= 
0.787, SUC p=0.587). Epididymal fat pad mass was significantly higher in the ASP 
group compared with the control group (5.50 ± 0.34 g, p=0.042). 
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Conclusion: No significant effect was seen from the moderate consumption of 
aspartame or sucralose on glucose tolerance. No significant differences were seen in 
weight or overall body fat. However, while percent body fat was unaffected, aspartame 
consumption at low doses may alter body fat distribution. These results may be of 
importance in preventing increased abdominal obesity.  
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CHAPTER 1 
INTRODUCTION 
 
 
 Obesity has become a significant health concern as it continues to be an 
underlying factor for many preventable disease states. Currently affecting more than 
one-third of Americans, obesity has been linked to life altering illnesses such as heart 
disease, certain types of cancer, musculoskeletal disorders, and diabetes mellitus type 
2.1 A comorbidity often seen with obesity is the development of impaired glucose 
tolerance. Abnormalities in the ability to metabolize glucose can lead to increased risk of 
developing pre-diabetes and if continued, type 2 diabetes mellitus (T2DM).2 Those who 
are even considered to be overweight, but not obese, are three times more likely to 
develop T2DM.3 Type 2 diabetes mellitus is responsible for 90-95% of all diabetes 
cases in the United States.4   
 To combat the effects of excess energy intake on obesity and glucose 
intolerance, low-energy and non-nutritive sweeteners (NNS) have been introduced as a 
replacement for traditional sucrose and fructose sweeteners, which contribute more 
energy. NNS have been seen as beneficial due to their lack of glucose and energy 
density for those attempting to regulate blood glucose and reduce excess adiposity. 
This provides an alternative for those who consume traditionally sweetened beverages, 
which are correlated with increased weight gain,5 insulin resistance through 
inflammation and b-cell dysfunction, increased visceral adiposity,6 cardiovascular 
disease,7 and more recently are linked to rheumatoid arthritis in women.8 Previous 
findings have shown the use of NNS to be correlated with weight loss and are 
recommended for those with glucose intolerance.9  
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 Acesulfame potassium, aspartame, saccharin, and sucralose are the most 
common low-energy sweeteners to be made available in the United States.10 These 
artificial sweeteners are sweeter than traditional sucrose. Aspartame has the effect of 
being 180 times sweeter, while sucralose is 600 times sweeter. This allows consumers 
to take in such low doses that they are deemed low-energy or nonnutritive. While found 
in a variety of foods, NHANES 2007-2008 reported diet beverages were the primary 
source of intake of NNS in the American diet.11 Other sources can include yogurts, gum, 
desserts, as well as other food products. While consumption is found in all ages and 
ethnicities, adult females were the most likely to consume NNS beverages on a regular 
basis. 
 The increase in obesity and prevalence in T2DM may be correlated with an 
increased reliance on NNS.11 Current research, which has mostly examined the 
physiological effects of consumption at the approved upper limits, has produced 
contrasting results. A significant effect from NNS consumption to increased BMI or 
adiposity, as well as impaired glucose tolerance, has been reported in most,12-16 but not 
all, studies.17 One study has reported on the moderate effects of aspartame 
consumption on blood glucose changes and body composition.9 Since many Americans 
rely on moderate consumption of NNS,18 a further examination of the relationship 
between moderate NNS consumption and body composition and blood glucose may be 
warranted. Therefore, the purpose of this study is to determine the effect of moderate 
consumption of NNS (aspartame and sucrose) on glucose tolerance and body 
composition in an animal model. 
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Purpose: The purpose of this study was to determine the effect of moderate 
consumption of NNS (aspartame and sucralose) on glucose tolerance and body 
composition in an animal model. 
Research Hypothesis 
 
1) Is there a causal relationship between nonnutritive sweeteners and body 
composition? 
 Ho: Non-nutritive sweeteners will have no effect on body composition. 
 H1: Non-nutritive sweeteners will have an effect on body composition. 
2) Is there a causal relationship between nonnutritive sweeteners and glucose 
intolerance? 
 Ho: Non-nutritive sweeteners will have no effect on glucose tolerance. 
 H1: Non-nutritive sweeteners will have an effect on glucose tolerance. 
 
Definition of Terms 
 
ASB: Artificially sweetened beverages. Diet beverages that use non-nutritive 
sweeteners such as aspartame, sucralose, saccharin, stevia rebaudiana extract, and 
acesulfame potassium. These are used to replace traditional sweeteners in beverages 
such as high-fructose corn syrup or sucrose.  
NNS: Non-nutritive sweetener. High intensity sweeteners used in place of traditional 
sweeteners such as sucrose or fructose which do provide energy. Non-nutritive 
sweeteners are used in low doses relative to traditional sweeteners, leaving them with a 
minimal energy contribution. 
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OGTT: Oral glucose tolerance test examines the effect of a glucose load on the body to 
determine glucose tolerance concerns such as pre-diabetes, diabetes, or gestational 
diabetes. Measurements of serum insulin and blood glucose are tested every 15, 30, 
60, 90, and 120 minutes from the time of glucose load consumption. 
CPIR: Cephalic phase insulin response is the release of insulin following digestion of a 
meal. It has been seen in both humans and rats.19  
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CHAPTER 2 
REVIEW OF LITERATURE 
 
 
Non-Nutritive Sweeteners 
 
 NNS are a common ingredient in many types of foods, as well as used as an 
added sweetener for many attempting to reduce the added energy intake from 
traditional sweeteners. Two popular sources of NNS are aspartame and sucralose. Both 
are found in the most common sources of NNS for adults and children, which are diet 
beverages, followed by packaged artificial sweetener pouches, which are used as a 
topical additive for foods or beverages.11  
 Aspartame is enzymatically broken down from its molecular formula C14H18N2O5 
by esterases and peptidases. It is then metabolized as phenylalanine, aspartic acid, and 
methanol.20 Phenylalanine is an essential amino acid and precursor to melanin, 
dopamine, norepinephrine, and thyroxine. Aspartic acid is a nonessential amino acid 
commonly found in sugar cane that can be used as a neurotransmitter.21 Both 
phenylalanine and aspartic acid are commonly found in natural food sources such as 
meats, grains, and dairy products. As with their natural counterparts, the metabolized 
products of aspartame are broken down in the body and do not accumulate. Methanol is 
metabolized at a slower rate than other alcohols, such as ethanol, but is readily 
digested.22 Methanol is initially converted to formaldehyde in the liver. It then is 
converted to formic acid, and is excreted through urine. The amount of formaldehyde 
derived from aspartame is minute, as the body naturally contains amounts significantly 
greater than what is found in a serving of this NNS.18 Long term consumption of 
aspartame is considered safe up to 50 mg/kg per day, although most adults consume 3 
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mg/kg per day. When long term users of aspartame at the dose of 75mg/kg per day 
were compared to a control group, no significant differences in standard serum values, 
blood formate, or 24-hour urinary excretion were seen.23 
 Sucralose C12H19Cl3O8 is a chlorinated NNS derived from sucrose C12H22O11. 
Three hydroxyl groups in sucrose are replaced with three chlorine atoms to form 
sucralose.24 Unlike aspartame, which is broken down through digestion, sucralose 
remains unchanged and is excreted intact.18 Sucralose remains stable when exposed to 
higher temperatures. It then provides an appropriate use for baked goods and expands 
its use outside of diet beverages. Sucralose’s added range of thermal flexibility allows it 
to be used in 15 food and beverage categories. Sucralose has fewer concerns for 
health implications than other NNS, resulting in its use in 80 countries. Sucralose has 
an acceptable daily intake of 5 mg/kg per day, but the average adult consumes 1.6 
mg/kg per day. 
 
Obesity 
 
 Obesity has become a significant health concern as it continues to be an 
underlying factor for many preventable disease states. Overweight is defined by a body 
mass index (BMI) over 25, while obesity is indicated with a BMI over 30. The increased 
body mass is related to excessive adipose tissue which can present health risks.25 The 
rising prevalence of overweight and obesity leads to increased medical costs. As of 
2003, there were an estimated 75 billion dollars spent on obesity related costs, with half 
being financed through Medicare and Medicaid.26 As of 2008 this estimate grew 
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drastically to 147 billion dollars having been spent on obesity related medical care, 
proving it to not only be a health issue, but an economic concern as well.1 
 Increased adiposity leads to the development of overweight and obesity. These 
conditions resulting from increased weight lead to stress on the body and further health 
implications in many body systems.4 Hypertension is three times greater in those who 
are obese than those of a normal weight class. Elevated levels of LDL cholesterol and 
reduced HDL from increased weight lead to greater risk for coronary artery disease. 
These effects on the heart increase the risk of angina, sudden cardiac death, and 
myocardial infarction in obese individuals. Weight gain affects other systems, such as 
respiratory issues with the development of sleep apnea. Reproductive complications 
also occur from the development of excess weight, including reduced testosterone, 
increased estrogen, increased risk of polycyclic ovary syndrome, increased gestational 
diabetes, and increased birth defects in those who are pregnant. 
 While NNS were originally intended to decrease energy consumption and provide 
a solution for weight control, current research has reported a significant effect between 
increased BMI and higher NNS consumption.12-14 Increases in the incidence of obesity 
and NNS consumption may be coincidental or causal. Yet further examination of this 
relationship has been researched without a definitive conclusion. 
 
NNS’s Effect on Energy Intake 
 
 It has been reported that NNS reduces energy consumption, yet increases in 
adiposity and BMI are still correlated to the use of NNS. Long term prospective research 
by Stellman and Garfinkel (1988) found the use of NNS users had an increased BMI.14 
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Of the 78,692 subjects studied, BMI in the lowest quartile of NNS users was increased 
by 12.9%, while the BMI in the highest quartile increased by 29.8%. An examination of 
the diet patterns of NNS users found that they consumed significantly more vegetables 
and lean proteins, favoring less energy dense foods than those who did not use NNS. 
This suggested that BMI increases in NNS users were not likely to be from poor diet 
choices or that the consumption of NNS lead to increased energy consumption. 
 Fowler et al. (2008) studied the effects of NNS intake in 3,682 participants over a 
9 year period, and found that BMI increased by 47% in NNS users.12 The percent of 
energy from protein, total fat, and saturated fat was higher in artificially sweetened 
beverage users (ASB). However, Fowler found total energy, energy from carbohydrates 
and sucrose, as well as alcohol consumption, were significantly lower in the NNS 
consumers than in subjects who abstained from NNS,12 which contrasts findings of 
Stellman and Garfinkel (1988).14 This suggests that the use of NNS lead to reduced 
energy intake when used as a substitute to energy dense sweeteners.  
 When energy intake was controlled in Winstar rats, consumption of NNS flavored 
yogurt led to a 28% greater weight gain in those that consumed saccharin, and a 20% 
increase in weight in the rats that consumed aspartame.13 However other research in 
animal models found aspartame based NNS did not lead to increased intake in food or 
increases in weight in mice.15 
 The effect of NNS on reducing energy intake has been demonstrated, but 
showed contrasting results on BMI. The effect of moderate consumption of NNS on 
body composition in rats found that rats who consumed aspartame had lower body fat 
percentages, which was attributed to decreased energy intake.9 This could be related to 
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the lower amounts of NNS used in this study, since other research used on greater 
quantities in the diet for treatment groups and found that body fat was increased.16, 17 
However, a meta-analysis of 1,951 adults and children found consumption of low 
energy sweeteners, such as diet NNS beverages, to decrease body weight by 0.80 kg.27 
While this loss appears to be minimal, a significant overall reduction in BMI, adiposity, 
and waist circumference was found. 
 
Digestive Signaling from NNS 
 
  An alternative hypothesis on the relationship between increased BMI and NNS is 
that NNS do not provide satiety in the way traditional sweeteners do, which may lead to 
the increased consumption of food.28 The cephalic phase of digestion begins with the 
activation of hormonal secretions necessary for the digestion and absorption of 
nutrients. The cephalic phase can be triggered by sensations such as sight, smell, and 
the detection of sweet flavored foods.29 Taste sensations are detected by G protein-
coupled receptors (GLP-1), while the specific T1R2 and T1R3 receptors are responsible 
for signaling sweetness by coupling with GLP-1.30 These taste receptors have been 
found to be stimulated by NNS, such as saccharin and acesulfame potassium.31 
However, the effect of sucralose is inconclusive as it has been shown to activate GLP-1 
through T1R2 and T1R3 in vitro,32 yet when examined in healthy human subjects, there 
were no increases in GLP-1 indicating sucralose did not stimulate sweetness 
receptors.30 For those NNS which have shown an effect, the signaling of sweetness 
would then elicit activation of the cephalic phase, which has been found to possibly 
increase hunger signals leading to increased energy consumption.33 
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 Part of the cephalic phase is the activation of the insulin response (CPIR), a 
neural stimulation from the vagus nerve that elects a cascade of hormones necessary 
for activation of digestion, particularly the stimulation of insulin secretion from beta cells 
in the pancreas.19 Initial insights on CPIR suggested that it could be activated by energy 
stimulation. However, more recent research has found a stimulation of CPIR from the 
sensation of sweetness, even when it is derived from non-energy dense sources. It has 
been found that the NNS saccharin has elicited a response similar to glucose, resulting 
in stimulation of the CPIR.34 However, no stimulation of the CPIR was reported when 
aspartame was ingested.29,35 If NNS are causing a stimulation in CPIR, ingestion of 
NNS with a carbohydrate load could result in greater glucose absorption, which places 
consumers at greater risk for glucose intolerance, and possibly obesity.36 
 
Glucose Intolerance 
 
 A comorbidity often seen with obesity is the development of impaired glucose 
tolerance. Abnormalities in the ability to metabolize glucose can lead to increased risk of 
developing pre-diabetes and if continued, T2DM.37 Those who are even considered to 
be overweight, but not obese, are three times more likely to develop T2DM.3 T2DM is 
responsible for 90-95% of all diabetes cases in the United States.4 Increased abdominal 
adiposity correlates to increased plasma free fatty acids which lead to the secretion of 
insulin from the pancreas. Excessive stimulation can increase insulin resistance in the 
peripheral tissues, reduce the uptake of glucose, and increase hepatic glucose 
production. T2DM isn’t initially correlated with the inability to produce insulin, but the 
recipient cells become defective, forming a resistance to insulin. This leads to increased 
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stress on the pancreas to increase insulin production, resulting in damage to the beta 
cells. Fasting hyperglycemia occurs from glucose circulating as decreased sensitivity to 
insulin or a decreased insulin response prevents glucose uptake.37  
 T2DM can result from multiple risk factors contributing to metabolic syndrome.4 
Metabolic syndrome is characterized by displaying at least three of the following: 
abdominal obesity (≥ 40in waist circumference in men or ≥ 35in waist circumference in 
women), insulin resistance (100mg/dL fasting plasma glucose), dyslipidemia from high 
triglyceride (≤ 150mg/dL) or cholesterol values (<40 mg/dL in men and <50 mg/dL in 
women), or hypertension (≥130/85 mmHg). Weight gain of 11-18 pounds can double the 
risk of developing T2DM. Excessive visceral adipose tissue contributing to a greater 
waist circumference increases risk of developing glucose intolerance further.  
 Prediabetes is characterized by a fasting blood glucose level of 100 - 125 
mg/dL.1 Those with pre-diabetes alone have an 8.5% greater risk of developing 
cardiovascular disease over a ten year period. This is twice the risk that would be seen 
in a normoglycemic individual.2 As of 2011, the development of diabetes had occurred 
in 20.9 million Americans, having tripled in occurrence since 1980.38 Rates of death due 
to diabetes related complications are expected to double between 2005 and 2030.39  
 NNS have been marketed to assist those who are sensitive to glucose due to 
metabolic derangements contributing to hyperglycemia. The use of NNS as a 
replacement for traditional sweeteners was thought to be beneficial in that it would 
provide a lower rise in blood glucose, as they do not contain larger amounts of 
carbohydrate as traditional sweeteners do. The effects of NNS on blood glucose and 
insulin release, which can affect metabolic conditions, were not heavily investigated until 
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recently. Research has led to findings showing that the use of NNS may contribute to 
glucose intolerance, providing the opposite effect of what many hyperglycemic patients 
depend on it for.9,16,40,41  
 Daily consumers of NNS containing diet sodas were assessed for diabetic risk in 
a study of 6,814 participants between the ages of 45-84. Those who consumed at least 
one serving of diet soda per day had a 67% higher risk of developing type 2 diabetes 
when compared to non-consumers.40 Larger waist circumferences were also found in 
users of NNS, which has been found to be a risk factor for diabetes.42 
 When sucralose was administered to 17 obese subjects prior to a 5 hour glucose 
tolerance test, significant increases were seen, indicating glucose intolerance.43 A single 
serving of sucralose similar to dosing found in a 12 oz can of diet soda was ingested in 
the treatment group prior to testing, while the control subjects consumed water. The 
results of the OGTT showed a significantly increased peak insulin response (p=0.02), 
increased insulin area under the curve (p=0.03), and increased peak plasma glucose 
concentrations (p=0.03). 
 Due to the significant affect that dietary intake and physical activity can have on 
blood glucose and insulin, animal models have been the primary form of research on 
this topic. Human studies leave a greater margin for error in the validity of results, as 
controlling diet and limiting physical activity are not easily obeyed. In order to ensure 
confounding variables have not swayed results, rat and mice studies have been 
conducted where diet and activity can be easily controlled.  
 To examine the effects of NNS on blood glucose changes with a controlled diet, 
Palmnäs et al. (2014) used male Sprague-Dawley rats as a model.9 The rats were put 
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on either a standard chow or a high fat diet, with the control of water or a moderate 
dose (5-7 mg/kg per day) of aspartame infused water as a treatment. The aspartame 
consumption correlated to increased fasting hyperglycemia as well as an impaired 
insulin tolerance, regardless of diet. The authors suggested that the aspartame impaired 
insulin mediated suppression of hepatic glucose output. Mitsutomi et al. (2013) had 
examined the relationship of NNS intake to insulin and glucose responses, by adding 
aspartame to the water of mice.15 After 8 weeks of consuming either a control of water, 
water with sucrose, or water with aspartame, glucose tolerance was assessed with an 
oral glucose tolerance test (OGTT). Insulin, glucose, and triglyceride levels were 
significantly increased in the NNS group compared to controls, suggesting that NNS 
intake impaired glucose tolerance. 
 Suez et al. confirmed these findings by adding saccharin, sucralose, and 
aspartame to the drinking water of mice.16 After 11 weeks of consumption, the NNS 
groups had significantly increased glucose intolerance. To determine if the NNS were 
the causative factor for glucose intolerance, the authors examined NNS consumption 
among 381 non-diabetic individuals. NNS consumption was correlated with markers/risk 
factors for hyperglycemia, including increased waist-to-hip ratio and glycosylated 
hemoglobin. 
 The source of changes in glucose tolerance from NNS is an emerging field of 
research. In rat models, the consumption of NNS was seen to alter glucose absorption 
on the membrane of enterocytes.41 The addition of sucralose or acesulfame potassium 
doubled the rate of post prandial glucose absorption 5 to 20 minutes after consumption. 
This was the result of the NNS increasing the presence of GLUT2 transporters in the 
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intestine to assist with glucose uptake. Glucose absorption into the intestinal epithelial 
cell is dependent on sodium co-transport (SGLT transport protein) and GLUT2 
transporters, which facilitate glucose uptake. If NNS and carbohydrate sources are 
consumed together, their collaborative effect could increase glucose uptake into the 
blood, causing hyperglycemia. Long term elevation of blood glucose could then damage 
pancreatic islet cells from over production of insulin leading to glucose intolerance.  
 Other research using rat models has focused on changes in body composition 
and glucose metabolism related to the NNS induced changes in the microbiota in the 
gut.9,16 Suez et al. investigated the relationship of NNS on glucose intolerance by 
performing a fecal transplant with the microbiota from NNS treated rats, into rats who 
had not consumed NNS. Following transplantation, the recipient mice exhibited glucose 
intolerance, leading to the suggestion that NNS consumption’s effects on metabolism of 
glucose are related to changes in the gut microbiota. 
 Contrasting results on glucose tolerance have also been seen. In ten healthy 
subjects, differences in blood glucose and plasma GLP-1 were assessed, after 
receiving an infusion of sucralose or saline. No significant differences were found 
between treatments, in contrast to previously reported studies.32 Further research is 
needed to determine the definitive effects of NNS on glucose tolerance and weight gain. 
Currently there is one study that looks at the effects of moderate consumption of 
aspartame on these variables,9 while other research has focused on higher intakes that 
may be above what the average adult consumer uses.16 
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CHAPTER 3 
METHODOLOGY 
 
 
 Sprague-Dawley male rats (Taconic Biosciences, Rensselaer, NY) were housed 
in pairs (N=30) in a 12 hr light/dark cycle in UNLV’s Laboratory Animal Care Facilities. 
Animals were randomly assigned to one of three groups where they were each fed a 
standard chow diet, with the inclusion of a treatment. Treatments include the addition of 
commercially available aspartame (Merisant, Chicago, IL) or sucralose (Heartland Food 
Products Group, Carmel, IN). Treatment dosing for aspartame (8.47 mg/kg/day) and 
sucralose (2.6 mg/kg/day) was formulated based on each groups mean weight, which 
was measured weekly. The three treatment groups were as follows (n=10) aspartame 
(ASP), sucralose (SUC), and a control of water (CON). Animals had no significant 
differences in weight between the ASP (147.2 ± 2.2 g), SUC (152.9 ± 2.6 g), and CON 
(152.2 ± 1.4 g) at the start of the study (p=0.13). All animals were given food ad libitum 
for 6 weeks prior to testing and sacrifice.  
 Subjects were weighed once per week to monitor growth and formulate weekly 
treatment dose. Following overnight fasting, an oral glucose tolerance test was 
administered at the completion of the 6-week study. A fasting blood glucose and serum 
insulin sample was taken prior to administering a glucose load. Rats were then 
administered an oral glucose load via oral gavage of 2 g/kg dose of 50% weight/volume 
dextrose solution, with samples then being taken every 15, 30, 60, and 120 minutes of 
load. Blood glucose was examined immediately through use of a Bayer glucose monitor 
and test strips. Blood samples (300 µl) for insulin were collected into microcapillary 
tubes via tail bleeding. Insulin samples were centrifuged to isolate plasma and stored at 
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-70° C for later analysis. Insulin assessment was completed with the use of a 
radioimmunoassay for insulin sensitive rats (Millipore Corp, Billerica, MA).  
Assessments of lean mass and fat mass were determined from the use of dual 
energy x-ray absorptiometry (DEXA) with small animal software (Lunar Prodigy, 
General Electric) immediately following sacrifice at the completion of the 6 week 
treatment period. Standard values for animals were used for compliance with the small 
animal software. Standard DEXA values included height of 10 inches, and weight of 0.3 
lbs. Removal of the epididymal fat pads was conducted following the DEXA scan, and 
were immediately weighed. 
 
Statistical Analysis 
 
 Statistical analysis was performed with Statistical Package for the Social 
Sciences (SPSS) 22.0 software (Armonk, New York). One-way analysis of variance 
(ANOVA) and post hoc Tukey’s tests was used to identify the differences in the 
dependent measures between groups. Significance was set to p<0.05. Area under the 
glucose and insulin response curves (AUC) were calculated via the trapezoid method. 
Data are reported by analyzing the mean ± SEM. 
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CHAPTER 4 
RESULTS 
 
Glucose Tolerance 
 
Following the 6 week intervention treatment of water with aspartame (ASP), water 
with sucralose (SUC), or control (CON), no significant differences were seen in the 
results of oral glucose tolerance testing. ASP (p=0.282) and SUC (p=0.870) areas 
under the glucose concentration curve (AUC) were not significantly different from the 
CON group AUC (Table 1, Figure 1). Individual time points were analyzed for 
significance. No significant differences were found at 0 min (ASP p=0.897, SUC 
p=0.435), 15 min (ASP p=0.930, SUC p= 0.952), 30 min (ASP p=0.319, SUC p=0.472), 
60 min (ASP p=0.550, SUC p=0.999), or 120 min (ASP p=0.161, SUC p= 0.849) 
between the NNS groups and the control group (Table 1, Figure 2).  
Table 1: OGTT Serum Glucose Comparison 
 
Treatment 
 
0 min 
(mg/dL) 
15 min 
(mg/dL) 
30 min 
(mg/dL) 
60 min 
(mg/dL) 
120 min 
(mg/dL) 
AUC 
(mg/dL/120min) 
ASP (n=10) 52.8 ± 2.8 84.3 ± 5.2 94.6 ±6.2 91.1 ± 6.3 75.4 ± 8.0 10,150.5 ± 595.0 
SUC (n=10) 58.9 ± 2.1 79.2 ± 3.7 92.5 ± 3.7 84.5 ± 3.1 65.3 ± 2.3 9,472.5 ± 231.0 
CON (n=10) 54.4 ± 2.7 81.5 ± 6.9 83.9 ± 5.2 84.2 ± 3.6 61.2 ± 3.8 9147.9 ± 465.7 
Values are mean ± standard error; (p>0.05) 
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Figure 1: OGTT Serum Glucose Area Under The Curve  
 
 
Area under the glucose concentration curve for aspartame (ASP), Sucralose (SUC), and  
control (CON).  
 
Figure 2: OGTT Serum Glucose 
 
 
Glucose response for aspartame (ASP), Sucralose (SUC), and control (CON) from OGTT.  
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 A viable sample for plasma insulin at each time point was collected on animals 
from the ASP group (n=6), SUC group (n=7), and CON group (n=6). The areas under 
the insulin concentration curve were not significantly different between the NNS groups 
(ASP p= 0.120, SUC p=0.456) and the control (Table 2, Figure 3). No significant 
differences were seen at 0 min (ASP p=0.980, SUC p=0.350), 15 min (ASP p=0.159, 
SUC p= 0.601), 30 min (ASP p=0.667, SUC p=0.411), 60 min (ASP p=0.677, SUC 
p=0.806), or 120 min (ASP p=0.756, SUC p= 0.282) between either NNS group and the 
control group (Table 2, Figure 4).  
 
Table 2: OGTT Plasma Insulin Comparison 
 
Treatment 
 
0 min 
(mg/dL) 
15 min 
(mg/dL) 
30 min 
(mg/dL) 
60 min 
(mg/dL) 
120 min 
(mg/dL) 
AUC 
(mg/dL/120min) 
ASP (n=6) 0.63 ± 0.19 0.60 ± 0.07 0.51 ± 0.08  0.52 ± 0.09 0.49 ± 0.09 63.1 ± 5.7 
SUC (n=7) 0.49 ± 0.08 0.77 ± 0.11 0.75 ± 0.06 0.55 ± 0.05 0.48 ± 0.06 71.2 ± 3.2 
CON (n=6) 0.66 ± 0.12 0.93 ± 0.15 0.61 ± 0.09 0.63 ± 0.12 0.72 ± 0.18 81.4 ± 8.6 
Values are mean ± standard error; (p>0.05) 
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Figure 3: OGTT Plasma Insulin Area Under The Curve  
 
 
Area under the glucose concentration curve for aspartame (ASP), Sucralose (SUC), and  
control (CON).  
 
Figure 4: OGTT Plasma Insulin  
 
 
Insulin response for aspartame (ASP), Sucralose (SUC), and control (CON) from OGTT.  
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Body Composition 
 
Epididymal fat pad mass was significantly higher in the ASP group compared 
with the control group (5.50 ± 0.34 g, p=0.042) (Table 3, Figure 5). However, changes in 
body mass from the beginning of treatment to the completion were not significantly 
different between each of the NNS groups (ASP p= 0.787, SUC p=0.587) and the 
control group (Table 3, Figure 6). Percent body fat was measured by DEXA (Table 3, 
Figure 7). While the ASP group (19.30 ± 0.70%) had a higher mean body fat percentage 
than both SUC (17.7 ± 0.67%) and CON group (17.79 ±  0.91%), results were not 
significantly different (ASP group, p= 0.273; SUC group, p=0.994; vs. CON).  
Figure 5: Mass of Epididymal Fat Pads 
 
 
Epididymal fat pad weight for aspartame (ASP), Sucralose (SUC), and control (CON). * Significantly  
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Figure 6: Body Mass Change  
 
 
Body mass changes for aspartame (ASP), Sucralose (SUC), and control (CON).  
 
 
Figure 7: Total Body Fat Percent  
 
 
Total body fat percent for aspartame (ASP), Sucralose (SUC), and control (CON).  
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Table 3: Body Composition Assessments Comparison 
Values are mean ± standard error; (p>0.05) 
 
 
 
 
 
 
 
 
 
 
  
 ASP (n=10) SUC (n=10) CON (n=10) 
Body Fat (%) 19.3 ± 0.70 17.7 ± 0.67 17.59 ± 2.88 
Weight Gain (g) 232.7 ± 9.79 249.2 ± 5.29 239.30 ± 5.00 
Weight of Epididymal Fat Pads (g) * 5.5 ± 0.34 5.0 ± 0.24 4.55 ± 0.19 
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CHAPTER 5 
DISCUSSION AND IMPLICATIONS 
 
 
Artificial sweeteners (NNS) are a common ingredient in many types of foods to 
reduce the added energy intake from traditional sweeteners. Two of the most popular 
NNS are aspartame and sucralose, which are found in diet beverages and packaged 
artificial sweetener packets.11 While NNS were originally intended to decrease energy 
consumption and provide a solution for weight control, a connection between increased 
BMI and higher NNS consumption has been reported.12-14  
Previous research on the effects of NNS on glucose tolerance and body 
composition changes in humans consist primarily of observational studies, with few 
intervention studies.9,13,15,16 When energy intake was controlled in rats, consumption of 
NNS flavored yogurt led to a 28% greater weight gain in those that consumed 
saccharin, and a 20% increase in weight in the rats that consumed aspartame.13 
However other research in animal models found aspartame based NNS did not lead to 
increased intake in food or increased weight in mice.15   
 The effects of NNS on blood glucose changes have been studied using rats as a 
model.9 Fasting hyperglycemia as well as an impaired insulin tolerance was correlated 
to aspartame consumption in rats given a moderate dose (5-7 mg/kg per day) of 
aspartame infused water as a treatment, regardless of diet, suggesting that aspartame 
impaired insulin mediated suppression of hepatic glucose output. Similarly, insulin, 
glucose, and triglyceride levels were significantly increased in the NNS treated mice 
compared to control animals, suggesting that NNS intake impaired glucose 
tolerance.15,16  Research has led to findings showing that the use of NNS may 
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contribute to glucose intolerance; the opposite effect of what many hyperglycemic 
patients are expecting.9,16,40,42 Further, several studies that included an intervention 
treatment of aspartame used doses significantly exceeding the average adult intake of 
3mg/kg/day.13,15,16,18 The body of research examining glucose tolerance or body 
composition changes from the NNS sucralose is much smaller. Sucralose has been 
seen to increase post prandial glucose consumption by raising the amount of glucose 
transporters.41 However, intervention strategies assessing moderate doses of sucralose 
consumption have not been seen. Therefore, the purpose of this study was to determine 
the effect of moderate consumption of non-nutritive sweeteners on glucose tolerance 
and body composition in an animal model. 
 In this study, no significant differences were found in either NNS group when 
compared to the control for glucose or insulin from oral glucose tolerance testing. While 
the ASP group did have higher trending OGTT values for serum blood glucose, 
significance was not found. This result varies from previous research which found a 
relationship between moderate levels of aspartame consumption and impaired glucose 
tolerance.9 Palmnäs et al., used a similar dose (5-7 mg/kg/day) of aspartame to that 
used in this study (8.5 mg/kg/day). However, significantly higher values in fasting 
glucose were seen in the aspartame vs control group in the previous study. No 
significant differences in the plasma insulin response to the oral glucose load were 
found in our study, which deviates from the previously published research on aspartame 
at low doses.9 The primary variation in methods between this study and that of Palmnas 
et al., was in the the duration of treatment (8 weeks of NNS treatment in the previous 
study vs. 6 weeks in the present study).  
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Previous research on sucralose and impaired glucose tolerance has been limited. 
Research in humans found a significant effect from the consumption of sucralose, 
however this effect was not replicated in the current findings.43 Disparities may be seen 
from the different subject models or methods. In the human research, sucralose was 
administered once immediately prior to a OGTT, whereas this study focused on low doses 
over a 6 week period, and animals were fasted prior to oral glucose tolerance testing. 
Other research examining possible relationships between NNS and glucose 
tolerance focused on higher treatment doses of aspartame, concluding a potential effect 
on reducing glucose tolerance.15,16 Increases in area under the glucose concentration 
curve were seen in NNS treated groups compared to the control. This follows trends seen 
in previous studies.15,16 However, differences seen in AUC from the moderate dose of 
NNS administered were not significant. Differences in the significance found in this study 
and results previously published may be due to the higher doses of NNS administered in 
previous research. The aspartame dose in this study was a 0.02% solution, which is 
significantly lower than the 4-5% solution used in similar studies that found significantly 
impaired glucose tolerance.15,16 Increasing the administered dose beyond what is typically 
consumed in humans makes it difficult to determine if the effects seen with these higher 
doses will be replicated in a normal human population. Based on the findings of this study, 
moderate consumption of the artificial sweeteners aspartame and sucralose does not 
have a significant effect on glucose tolerance in a rat model.  
The epididymal fat pads were found to be significantly higher for the ASP group 
(p=0.042) compared to the CON group, suggesting that ASP may lead to redistribution of 
body fat stores. This confirms findings by Mitsutomi et al., which found the epididymal fat 
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pads to have greater mass following aspartame treatment.15 Epidemiological studies 
performed on humans found consumption of NNS in the form of ≥1 serving of diet soda 
can increase waist circumference significantly, supporting that a change in body 
composition may occur from NNS intake.40 Researchers have suggested increases in 
epididymal fat pads may relate to increased visceral adiposity in humans, indicating a 
higher risk for atherosclerosis and metabolic conditions.44 However, more research 
should be done to establish this specific connection. Weight changes from the start to the 
completion of the study were not significantly different between groups. Body fat percent 
was not significantly different between the ASP or SUC group when compared to the 
control. While the current findings do indicate increases in total body fat compared to the 
controls, results were not significant. While significance was not found, this is on trend 
with the findings seen in Palmnas et al., which had a significantly higher body fat percent 
for the low dose aspartame group. Both studies observed a lower final weight in the 
aspartame treated groups, however weight changes were not significant in either study. 
The NNS groups did exhibit higher total body fat than the control, but results were not 
significant, contrasting previous research conducted with higher doses of NNS.16 
Evidence presented in this study suggests a possible change in body fat distribution from 
the consumption of the NNS aspartame at low doses.  
 
Future Research 
 
 Future research regarding the relationship between NNS consumption and 
glucose tolerance and body composition in human models would be of benefit. A study 
design ensuring the inclusion of a treatment rather than observational analysis in humans 
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could further confirm findings seen at low doses of NNS treatment. This can be difficult 
as other factors such as diet and physical activity would require monitoring. Results seen 
in the study regarding glucose tolerance and body fat percent were not significant with 
the low dose treatment. As this contrasts findings at larger doses,13,15,16 a more in depth 
dose response relationship would be warranted to determine the threshold of significance 
from NNS consumption on glucose tolerance and body composition.  
 
Conclusion 
 
 In conclusion, this study showed no effect from the consumption of aspartame or 
sucralose on glucose tolerance. No significant differences were seen in weight or overall 
body fat. However, while percent body fat was unaffected, aspartame consumption at low 
doses may alter body fat distribution. These results may be of importance in preventing 
increased abdominal obesity. Increased abdominal fat stores are a marker for metabolic 
syndrome and can be a risk factor for glucose intolerance.4  
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APPENDIX I: ANOVA AND DESCRIPTIVE STATISTICS 
 
Descriptives 
Glucose AUC   
 N Mean Std. Deviation Std. Error 
95% Confidence Interval for 
Mean Minimum Maximum 
Lower Bound Upper Bound 
Asp 10 10150.5000 1881.43296 594.96134 8804.6039 11496.3961 7980.00 14025.00 
Suc 10 9472.5000 730.59051 231.03301 8949.8670 9995.1330 8025.00 10530.00 
Con 10 9147.8500 1469.36647 464.65448 8096.7285 10198.9715 6757.50 10995.00 
Total 30 9590.2833 1454.22028 265.50308 9047.2686 10133.2981 6757.50 14025.00 
 
 
ANOVA 
Glucose AUC   
 Sum of Squares df Mean Square F Sig. 
Between Groups 5234628.817 2 2617314.408 1.260 .300 
Within Groups 56093313.025 27 2077530.112   
Total 61327941.842 29    
 
 
Multiple Comparisons 
Dependent Variable:   Glucose AUC   
Tukey HSD   
(I) Treatment (J) Treatment Mean 
Difference (I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
Asp Suc 678.00000 644.59757 .551 -920.2266 2276.2266 
Con 1002.65000 644.59757 .282 -595.5766 2600.8766 
Suc Asp -678.00000 644.59757 .551 -2276.2266 920.2266 
Con 324.65000 644.59757 .870 -1273.5766 1922.8766 
Con Asp -1002.65000 644.59757 .282 -2600.8766 595.5766 
Suc -324.65000 644.59757 .870 -1922.8766 1273.5766 
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Descriptives 
Glucose 0 Min   
 N Mean Std. 
Deviation 
Std. 
Error 
95% Confidence Interval for 
Mean 
Minimum Maximu
m 
Lower Bound Upper Bound 
Asp 10 52.8000 8.96660 2.83549 46.3857 59.2143 36.00 66.00 
Suc 10 58.9000 6.53962 2.06801 54.2218 63.5782 48.00 68.00 
Con 10 54.4000 8.44854 2.67166 48.3563 60.4437 40.00 68.00 
Total 30 55.3667 8.20212 1.49749 52.3039 58.4294 36.00 68.00 
 
 
ANOVA 
Glucose 0 MIN   
 Sum of Squares df Mean Square F Sig. 
Between Groups 200.067 2 100.033 1.543 .232 
Within Groups 1750.900 27 64.848   
Total 1950.967 29    
 
 
Multiple Comparisons 
Dependent Variable:   Glucose 0 MIN   
Tukey HSD   
(I) Treatment (J) Treatment Mean 
Difference (I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
Asp Suc -6.10000 3.60134 .226 -15.0292 2.8292 
Con -1.60000 3.60134 .897 -10.5292 7.3292 
Suc Asp 6.10000 3.60134 .226 -2.8292 15.0292 
Con 4.50000 3.60134 .435 -4.4292 13.4292 
Con Asp 1.60000 3.60134 .897 -7.3292 10.5292 
Suc -4.50000 3.60134 .435 -13.4292 4.4292 
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Descriptives 
Glucose 15  min 
 N Mean Std. 
Deviation 
Std. 
Error 
95% Confidence Interval for 
Mean 
Minimum Maximu
m 
Lower Bound Upper Bound 
Asp 10 84.3000 16.62027 5.25579 72.4106 96.1894 64.00 115.00 
Suc 10 79.2000 11.82089 3.73809 70.7438 87.6562 63.00 99.00 
Con 10 81.5000 21.93551 6.93662 65.8083 97.1917 43.00 110.00 
Total 30 81.6667 16.82021 3.07094 75.3859 87.9474 43.00 115.00 
 
 
ANOVA 
Glucose 15  min 
 Sum of Squares df Mean Square F Sig. 
Between Groups 130.467 2 65.233 .218 .805 
Within Groups 8074.200 27 299.044   
Total 8204.667 29    
 
 
Multiple Comparisons 
Dependent Variable:   Glucose 15 min  
Tukey HSD   
(I) Treatment (J) Treatment Mean 
Difference (I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
Asp Suc 5.10000 7.73362 .789 -14.0749 24.2749 
Con 2.80000 7.73362 .930 -16.3749 21.9749 
Suc Asp -5.10000 7.73362 .789 -24.2749 14.0749 
Con -2.30000 7.73362 .952 -21.4749 16.8749 
Con Asp -2.80000 7.73362 .930 -21.9749 16.3749 
Suc 2.30000 7.73362 .952 -16.8749 21.4749 
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Descriptives 
Glucose 30 min   
 N Mean Std. 
Deviation 
Std. 
Error 
95% Confidence Interval for 
Mean 
Minimum Maximu
m 
Lower Bound Upper Bound 
Asp 10 94.6000 19.68756 6.22575 80.5164 108.6836 65.00 131.00 
Suc 10 92.5000 11.72130 3.70660 84.1151 100.8849 73.00 113.00 
Con 10 83.9000 16.29894 5.15418 72.2404 95.5596 62.00 107.00 
Total 30 90.3333 16.35666 2.98630 84.2257 96.4410 62.00 131.00 
 
 
ANOVA 
Glucose 30  min 
 Sum of Squares df Mean Square F Sig. 
Between Groups 642.867 2 321.433 1.220 .311 
Within Groups 7115.800 27 263.548   
Total 7758.667 29    
 
 
Multiple Comparisons 
Dependent Variable:   Glucose 30 min   
Tukey HSD   
(I) Treatment (J) Treatment Mean 
Difference (I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
Asp Suc 2.10000 7.26014 .955 -15.9009 20.1009 
Con 10.70000 7.26014 .319 -7.3009 28.7009 
Suc Asp -2.10000 7.26014 .955 -20.1009 15.9009 
Con 8.60000 7.26014 .472 -9.4009 26.6009 
Con Asp -10.70000 7.26014 .319 -28.7009 7.3009 
Suc -8.60000 7.26014 .472 -26.6009 9.4009 
 
 
 
 
 
 
 
 33 
Descriptives 
Glucose 60  min 
 N Mean Std. 
Deviation 
Std. 
Error 
95% Confidence Interval for 
Mean 
Minimum Maximu
m 
Lower Bound Upper Bound 
Asp 10 91.1000 20.01916 6.33061 76.7792 105.4208 71.00 135.00 
Suc 10 84.5000 9.86858 3.12072 77.4404 91.5596 70.00 100.00 
Con 10 84.3000 11.26499 3.56230 76.2415 92.3585 68.00 100.00 
Total 30 86.6333 14.29368 2.60966 81.2960 91.9707 68.00 135.00 
 
 
ANOVA 
Glucose 60  min 
 Sum of Squares df Mean Square F Sig. 
Between Groups 299.467 2 149.733 .719 .496 
Within Groups 5625.500 27 208.352   
Total 5924.967 29    
 
 
Multiple Comparisons 
Dependent Variable:   Glucose 60  min 
Tukey HSD   
(I) Treatment (J) Treatment Mean 
Difference (I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
Asp Suc 6.60000 6.45526 .569 -9.4053 22.6053 
Con 6.80000 6.45526 .550 -9.2053 22.8053 
Suc Asp -6.60000 6.45526 .569 -22.6053 9.4053 
Con .20000 6.45526 .999 -15.8053 16.2053 
Con Asp -6.80000 6.45526 .550 -22.8053 9.2053 
Suc -.20000 6.45526 .999 -16.2053 15.8053 
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Descriptives 
Glucose 120  min 
 N Mean Std. 
Deviation 
Std. 
Error 
95% Confidence Interval for 
Mean 
Minimum Maximu
m 
Lower Bound Upper Bound 
Asp 10 75.4000 25.44362 8.04598 57.1987 93.6013 58.00 146.00 
Suc 10 65.3000 7.13442 2.25610 60.1963 70.4037 54.00 79.00 
Con 10 61.2000 12.15456 3.84361 52.5052 69.8948 40.00 76.00 
Total 30 67.3000 17.30288 3.15906 60.8390 73.7610 40.00 146.00 
 
 
ANOVA 
Glucose 120  min 
 Sum of Squares df Mean Square F Sig. 
Between Groups 1068.200 2 534.100 1.894 .170 
Within Groups 7614.100 27 282.004   
Total 8682.300 29    
 
 
Multiple Comparisons 
Dependent Variable:   Glucose 120 min  
Tukey HSD   
(I) Treatment (J) Treatment Mean 
Difference (I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
Asp Suc 10.10000 7.51004 .383 -8.5205 28.7205 
Con 14.20000 7.51004 .161 -4.4205 32.8205 
Suc Asp -10.10000 7.51004 .383 -28.7205 8.5205 
Con 4.10000 7.51004 .849 -14.5205 22.7205 
Con Asp -14.20000 7.51004 .161 -32.8205 4.4205 
Suc -4.10000 7.51004 .849 -22.7205 14.5205 
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Descriptives 
Insulin  AUC 
 N Mean Std. 
Deviation 
Std. 
Error 
95% Confidence Interval for 
Mean 
Minimum Maximu
m 
Lower Bound Upper Bound 
ASP 6 63.1242 13.98617 5.70983 48.4466 77.8017 41.32 80.55 
SUC 7 71.1643 8.54774 3.23074 63.2589 79.0696 55.95 77.70 
CON 6 81.4017 20.94478 8.55067 59.4215 103.3819 54.60 113.33 
Total 19 71.8582 16.01632 3.67439 64.1385 79.5778 41.32 113.33 
 
 
ANOVA 
Insulin  AUC 
 Sum of Squares df Mean Square F Sig. 
Between Groups 1007.537 2 503.769 2.233 .140 
Within Groups 3609.866 16 225.617   
Total 4617.403 18    
 
 
Multiple Comparisons 
Dependent Variable:   Insulin  AUC 
Tukey HSD   
(I) Group (J) Group Mean Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
ASP SUC -8.04012 8.35666 .610 -29.6031 13.5228 
CON -18.27750 8.67211 .120 -40.6544 4.0994 
SUC ASP 8.04012 8.35666 .610 -13.5228 29.6031 
CON -10.23738 8.35666 .456 -31.8003 11.3256 
CON ASP 18.27750 8.67211 .120 -4.0994 40.6544 
SUC 10.23738 8.35666 .456 -11.3256 31.8003 
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Descriptives 
Insulin 0 min   
 N Mean Std. 
Deviation 
Std. 
Error 
95% Confidence Interval for 
Mean 
Minimum Maximu
m 
Lower Bound Upper Bound 
ASP 6 .6317 .04750 .01939 .5818 .6815 .58 .70 
SUC 7 .4886 .20301 .07673 .3008 .6763 .22 .69 
CON 6 .6550 .29710 .12129 .3432 .9668 .27 .99 
Total 19 .5863 .21180 .04859 .4842 .6884 .22 .99 
 
 
ANOVA 
Insulin 0 min   
 Sum of Squares df Mean Square F Sig. 
Between Groups .108 2 .054 1.229 .319 
Within Groups .700 16 .044   
Total .807 18    
 
 
Multiple Comparisons 
Dependent Variable:   Insulin 0 min   
Tukey HSD   
(I) Group (J) Group Mean Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
ASP SUC .14310 .11636 .454 -.1572 .4433 
CON -.02333 .12075 .980 -.3349 .2883 
SUC ASP -.14310 .11636 .454 -.4433 .1572 
CON -.16643 .11636 .350 -.4667 .1338 
CON ASP .02333 .12075 .980 -.2883 .3349 
SUC .16643 .11636 .350 -.1338 .4667 
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Descriptives 
Insulin 15 min   
 N Mean Std. 
Deviation 
Std. 
Error 
95% Confidence Interval for 
Mean 
Minimum Maximu
m 
Lower Bound Upper Bound 
ASP 6 .6033 .17862 .07292 .4159 .7908 .42 .87 
SUC 7 .7700 .27899 .10545 .5120 1.0280 .45 1.16 
CON 6 .9267 .37431 .15281 .5339 1.3195 .35 1.38 
Total 19 .7668 .30192 .06927 .6213 .9124 .35 1.38 
 
 
ANOVA 
Insulin 15 min   
 Sum of Squares df Mean Square F Sig. 
Between Groups .314 2 .157 1.891 .183 
Within Groups 1.327 16 .083   
Total 1.641 18    
 
 
 
Multiple Comparisons 
Dependent Variable:   Insulin 15 min   
Tukey HSD   
(I) Group (J) Group Mean Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
ASP SUC -.16667 .16023 .563 -.5801 .2468 
CON -.32333 .16627 .159 -.7524 .1057 
SUC ASP .16667 .16023 .563 -.2468 .5801 
CON -.15667 .16023 .601 -.5701 .2568 
CON ASP .32333 .16627 .159 -.1057 .7524 
SUC .15667 .16023 .601 -.2568 .5701 
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Descriptives 
Insulin 30 min   
 N Mean Std. 
Deviation 
Std. 
Error 
95% Confidence Interval for 
Mean 
Minimum Maximu
m 
Lower Bound Upper Bound 
ASP 6 .5117 .18809 .07679 .3143 .7091 .29 .79 
SUC 7 .7486 .15731 .05946 .6031 .8941 .49 .93 
CON 6 .6083 .23173 .09460 .3652 .8515 .36 1.05 
Total 19 .6295 .20805 .04773 .5292 .7297 .29 1.05 
 
 
ANOVA 
Insulin 30 min   
 Sum of Squares df Mean Square F Sig. 
Between Groups .185 2 .093 2.495 .114 
Within Groups .594 16 .037   
Total .779 18    
 
 
Multiple Comparisons 
Dependent Variable:   Insulin 3 0min   
Tukey HSD   
(I) Group (J) Group Mean Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
ASP SUC -.23690 .10718 .100 -.5135 .0397 
CON -.09667 .11123 .667 -.3837 .1903 
SUC ASP .23690 .10718 .100 -.0397 .5135 
CON .14024 .10718 .411 -.1363 .4168 
CON ASP .09667 .11123 .667 -.1903 .3837 
SUC -.14024 .10718 .411 -.4168 .1363 
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Descriptives 
Insulin 60 min   
 N Mean Std. 
Deviation 
Std. 
Error 
95% Confidence Interval for 
Mean 
Minimum Maximu
m 
Lower Bound Upper Bound 
ASP 6 .5150 .21436 .08751 .2900 .7400 .27 .81 
SUC 7 .5471 .14430 .05454 .4137 .6806 .32 .78 
CON 6 .6267 .30592 .12489 .3056 .9477 .32 1.15 
Total 19 .5621 .21890 .05022 .4566 .6676 .27 1.15 
 
 
ANOVA 
Insulin 60 min   
 Sum of Squares df Mean Square F Sig. 
Between Groups .040 2 .020 .388 .685 
Within Groups .823 16 .051   
Total .863 18    
 
 
Multiple Comparisons 
Dependent Variable:   Insulin 60 min   
Tukey HSD   
(I) Group (J) Group Mean Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
ASP SUC -.03214 .12615 .965 -.3577 .2934 
CON -.11167 .13091 .677 -.4495 .2261 
SUC ASP .03214 .12615 .965 -.2934 .3577 
CON -.07952 .12615 .806 -.4050 .2460 
CON ASP .11167 .13091 .677 -.2261 .4495 
SUC .07952 .12615 .806 -.2460 .4050 
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 Descriptives 
Insulin 120 min   
 N Mean Std. 
Deviation 
Std. 
Error 
95% Confidence Interval for 
Mean 
Minimum Maximu
m 
Lower Bound Upper Bound 
ASP 6 .4883 .21442 .08754 .2633 .7134 .21 .82 
SUC 7 .4829 .17260 .06524 .3232 .6425 .18 .69 
CON 6 .7183 .44678 .18240 .2495 1.1872 .14 1.50 
Total 19 .5589 .30089 .06903 .4139 .7040 .14 1.50 
 
 
ANOVA 
Insulin 120 min   
 Sum of Squares df Mean Square F Sig. 
Between Groups .223 2 .111 1.267 .308 
Within Groups 1.407 16 .088   
Total 1.630 18    
 
 
Multiple Comparisons 
Dependent Variable:   Insulin 120 min   
Tukey HSD   
(I) Group (J) Group Mean Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
ASP SUC .00548 .16496 .999 -.4202 .4311 
CON -.23000 .17119 .393 -.6717 .2117 
SUC ASP -.00548 .16496 .999 -.4311 .4202 
CON -.23548 .16496 .351 -.6611 .1902 
CON ASP .23000 .17119 .393 -.2117 .6717 
SUC .23548 .16496 .351 -.1902 .6611 
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Descriptives 
Weight Change   
 N Mean Std. 
Deviation 
Std. 
Error 
95% Confidence Interval for 
Mean 
Minimum Maximu
m 
Lower Bound Upper Bound 
Asp 10 232.7000 30.94457 9.78553 210.5636 254.8364 174.00 290.00 
Suc 10 249.2000 16.73851 5.29318 237.2260 261.1740 215.00 278.00 
Con 10 239.3000 15.79768 4.99566 227.9990 250.6010 224.00 269.00 
Total 30 240.4000 22.56424 4.11965 231.9744 248.8256 174.00 290.00 
 
 
ANOVA 
Weight Change   
 Sum of Squares df Mean Square F Sig. 
Between Groups 1379.400 2 689.700 1.391 .266 
Within Groups 13385.800 27 495.770   
Total 14765.200 29    
 
 
Multiple Comparisons 
Dependent Variable:   Weight Change   
Tukey HSD   
(I) Treatment (J) Treatment Mean 
Difference (I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
Asp Suc -16.50000 9.95761 .240 -41.1891 8.1891 
Con -6.60000 9.95761 .787 -31.2891 18.0891 
Suc Asp 16.50000 9.95761 .240 -8.1891 41.1891 
Con 9.90000 9.95761 .587 -14.7891 34.5891 
Con Asp 6.60000 9.95761 .787 -18.0891 31.2891 
Suc -9.90000 9.95761 .587 -34.5891 14.7891 
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Descriptives 
Body Fat  % 
 N Mean Std. 
Deviation 
Std. 
Error 
95% Confidence Interval for 
Mean 
Minimum Maximu
m 
Lower Bound Upper Bound 
Asp 10 19.3000 2.21811 .70143 17.7133 20.8867 16.50 23.90 
Suc 10 17.7000 2.10660 .66617 16.1930 19.2070 13.80 21.40 
Con 10 17.5900 2.88230 .91146 15.5281 19.6519 13.30 23.20 
Total 30 18.1967 2.47268 .45145 17.2734 19.1200 13.30 23.90 
 
 
ANOVA 
Body Fat  % 
 Sum of Squares df Mean Square F Sig. 
Between Groups 18.321 2 9.160 1.556 .229 
Within Groups 158.989 27 5.888   
Total 177.310 29    
 
 
Multiple Comparisons 
Dependent Variable:   Body Fat %  
Tukey HSD   
(I) Treatment (J) Treatment Mean 
Difference (I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
Asp Suc 1.60000 1.08522 .319 -1.0907 4.2907 
Con 1.71000 1.08522 .273 -.9807 4.4007 
Suc Asp -1.60000 1.08522 .319 -4.2907 1.0907 
Con .11000 1.08522 .994 -2.5807 2.8007 
Con Asp -1.71000 1.08522 .273 -4.4007 .9807 
Suc -.11000 1.08522 .994 -2.8007 2.5807 
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Descriptives 
Weight of Epididymal Fat Pads 
 N Mean Std. 
Deviation 
Std. 
Error 
95% Confidence Interval for 
Mean 
Minimum Maximu
m 
Lower Bound Upper Bound 
ASP 10 5.4960 1.06671 .33732 4.7329 6.2591 4.00 7.40 
SUC 10 4.9970 .75208 .23783 4.4590 5.5350 3.76 6.33 
CON 10 4.5450 .60526 .19140 4.1120 4.9780 3.68 5.39 
Total 30 5.0127 .89354 .16314 4.6790 5.3463 3.68 7.40 
 
 
ANOVA 
Weight of Epididymal Fat Pads 
 Sum of Squares df Mean Square F Sig. 
Between Groups 4.526 2 2.263 3.280 .053 
Within Groups 18.629 27 .690   
Total 23.154 29    
 
 
Multiple Comparisons 
Dependent Variable:   Weight of Epididymal Fat Pads 
Tukey HSD   
(I) Treatment (J) Treatment Mean 
Difference (I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
ASP SUC .49900 .37147 .384 -.4220 1.4200 
CON .95100* .37147 .042 .0300 1.8720 
SUC ASP -.49900 .37147 .384 -1.4200 .4220 
CON .45200 .37147 .454 -.4690 1.3730 
CON ASP -.95100* .37147 .042 -1.8720 -.0300 
SUC -.45200 .37147 .454 -1.3730 .4690 
*. The mean difference is significant at the 0.05 level. 
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APPENDIX II: RAW DATA 
 
OGTT SERUM GLUCOSE VALUES 
  
Subject 
0 min 
(mg/dL) 
15 min 
(mg/dL) 
30 min 
(mg/dL) 
60 min 
(mg/dL) 
120 min 
(mg/dL) 
ASP - 1 46 74 94 135 146 
ASP - 2 49 82 65 84 66 
ASP - 3 63 99 131 109 76 
ASP - 4 36 65 78 72 58 
ASP - 5 57 77 101 95 69 
ASP - 6 54 99 104 104 72 
ASP - 7 55 93 113 83 66 
ASP - 8 45 75 78 79 62 
ASP - 9 57 64 80 71 64 
ASP - 10 66 115 102 79 75 
SUC - 11 58 63 87 94 66 
SUC - 12 51 99 113 90 61 
SUC - 13 60 64 92 93 69 
SUC - 14 53 81 91 100 79 
SUC - 15 48 81 93 83 63 
SUC - 16 61 71 80 84 63 
SUC - 17 67 71 73 71 54 
SUC - 18 62 83 93 70 66 
SUC - 19 68 91 108 78 73 
SUC - 20 61 88 95 82 59 
CON - 21 49 96 98 100 62 
CON - 22 40 65 68 72 59 
CON - 23 55 43 64 68 40 
CON - 24 44 57 62 75 44 
CON - 25 55 72 72 81 54 
CON - 26 60 89 89 92 69 
CON - 27 60 103 86 76 76 
CON - 28 68 80 101 96 66 
CON - 29 61 110 107 94 75 
CON - 30 52	 100	 92	 89	 67	
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OGTT SERUM INSULIN VALUES 
 
Subject 
Number 
0 min 
(ng/ml) 
15 min 
(ng/ml) 
30 min 
(ng/ml) 
60 min 
(ng/ml) 
120 min 
(ng/ml) 
ASP - 1 0.68	 0.42	 0.36	 0.81	 0.82	
ASP - 5 0.7 0.77 0.67 0.4 0.44 
ASP - 6 0.61 0.53 0.79 0.74 0.41 
ASP - 7 0.6 0.46 0.29 0.38 0.21 
ASP - 8 0.62 0.57 0.49 0.49 0.4 
ASP - 10 0.58 0.87 0.47 0.27 0.65 
SUC - 13 0.69 0.57 0.49 0.65 0.67 
SUC - 14 0.64 0.8 0.62 0.78 0.39 
SUC - 15 0.26 1.16 0.8 0.48 0.47 
SUC - 17 0.62 0.45 0.74 0.5 0.18 
SUC - 18 0.35 1.09 0.93 0.52 0.48 
SUC - 19 0.22 0.81 0.74 0.58 0.69 
SUC - 20 0.64 0.51 0.92 0.32 0.5 
CON - 22 0.84 1.03 1.05 1.15 0.54 
CON - 23 0.32 0.95 0.52 0.4 1.5 
CON - 26 0.27 0.65 0.36 0.54 0.62 
CON - 27 0.67 1.2 0.56 0.54 0.82 
CON - 29 0.99 1.38 0.58 0.81 0.14 
CON - 30 0.84	 0.35	 0.58	 0.32	 0.69	
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WEIGHT 
 
 
Subject 
Week 1 
(g) 
Week 2 
(g) 
Week 3 
(g) 
Week 4 
(g) 
Week 5 
(g) 
Week 6 
(g) 
ASP - 1 137 208 264 321 362 356 
ASP - 2 144 202 262 325 354 368 
ASP - 3 157 203 312 400 442 447 
ASP - 4 135 202 269 325 350 363 
ASP - 5 151 218 294 367 390 417 
ASP - 6 150 217 286 348 405 398 
ASP - 7 150 225 297 354 385 367 
ASP - 8 154 217 276 329 353 328 
ASP - 9 149 217 288 337 365 378 
ASP - 10 145 208 277 334 370 377 
SUC - 11 153 234 302 371 404 415 
SUC - 12 161 238 301 368 406 415 
SUC - 13 150 222 285 347 383 393 
SUC - 14 157 230 298 356 385 396 
SUC - 15 158 222 309 389 426 436 
SUC - 16 153 224 299 361 400 409 
SUC - 17 156 234 303 371 410 414 
SUC - 18 162 226 296 357 399 407 
SUC - 19 136 203 277 336 372 378 
SUC - 20 143 211 270 319 348 358 
CON - 21 155 226 287 337 372 381 
CON - 22 150 212 270 332 361 374 
CON - 23 154 228 298 368 405 418 
CON - 24 151 221 275 328 365 377 
CON - 25 158 224 289 354 388 388 
CON - 26 142 207 265 336 369 378 
CON - 27 152 222 290 345 377 389 
CON - 28 151 215 282 347 385 397 
CON - 29 153 225 296 367 404 422 
CON - 30 156 217 281 342 380 391 
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BODY COMPOSITION 
 
 
Subject	 Body	Fat	(%)	 Epididymal	Pads	(g)	
ASP - 1	 17.1	 4	
ASP - 2	 16.5	 4.8	
ASP - 3	 20.8	 7.4	
ASP - 4	 18.4	 5.02	
ASP - 5	 17.9	 7.07	
ASP - 6	 18.3	 5.93	
ASP - 7	 21.4	 5.69	
ASP - 8	 19.3	 5.25	
ASP - 9	 19.4	 4.59	
ASP - 10	 23.9	 5.21	
SUC - 11	 21.4	 5.33	
SUC - 12	 13.8	 5.72	
SUC - 13	 18.2	 4.39	
SUC - 14	 16.8	 4.67	
SUC - 15	 17.4	 5.5	
SUC - 16	 17.6	 5.15	
SUC - 17	 18	 4.65	
SUC - 18	 15.4	 4.47	
SUC - 19	 19.2	 6.33	
SUC - 20	 19.2	 3.76	
CON - 21	 18.2	 5.26	
CON - 22	 13.3	 3.83	
CON - 23	 15.3	 4.45	
CON - 24	 18.4	 3.68	
CON - 25	 16.9	 5.39	
CON - 26	 16.2	 4.52	
CON - 27	 18.5	 4.11	
CON - 28	 23.2	 5.26	
CON - 29	 15.2	 4.26	
CON - 30	 20.7	 4.69	
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APPENDIX III: PROTOCOL FOR ANIMAL CARE AND USE 
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